Travere Therapeutics (Travere Therapeutics) Marketable Securities : $397.8 Mil (As of Mar. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Travere Therapeutics's Marketable Securities for the quarter that ended in Mar. 2024 was $397.8 Mil.

Travere Therapeutics's annual Marketable Securities increased from Dec. 2021 ($387.1 Mil) to Dec. 2022 ($388.6 Mil) and increased from Dec. 2022 ($388.6 Mil) to Dec. 2023 ($508.7 Mil).

Travere Therapeutics Marketable Securities Historical Data

The historical data trend for Travere Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Marketable Securities Chart

Travere Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Marketable Securities

Get a 7-Day Free Trial

336.09

276.82

387.13

388.56

508.68

Travere Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Marketable Securities	Get a 7-Day Free Trial															400.14	420.46	490.40	508.68	397.79

Travere Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Travere Therapeutics (NAS:TVTX) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Travere Therapeutics Marketable Securities Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Travere Therapeutics (Travere Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130

Website

https://www.travere.com

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Executives

Jula Inrig	officer: Chief Medical Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Peter Heerma	officer: Chief Commercial Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote	officer: Senior Vice President, R&D	C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline	officer: Chief Financial Officer	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube	director, officer: Chief Executive Officer	3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Elizabeth E Reed	officer: SVP, GC & Corporate Secretary	9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Sandra Calvin	officer: VP, Corp Controller and CAO	3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Laura Clague	officer: Chief Financial Officer	370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage	director	6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams	director	C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg	officer: Chief Medical Officer	C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane	officer: Chief Operating Officer	C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Sandra Poole	director	830 WINTER STREET, WALTHAM MA 02451
Ron Squarer	director	C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066